Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial Huib A.M. Kerstjens, MD, PhD, Bernd Disse,

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Volume 129, Issue 3, Pages (March 2006)

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

What drives prescription patterns in pediatric asthma management?

Jonathan Malka, MD, David T

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Risk of an asthma exacerbation after bariatric surgery in adults

Anne M. Fitzpatrick, PhD, MSCR, W. Gerald Teague, MD

Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma Virginia Norris, MRCP, Lee Choong, BSc, Duyen Tran,

The prevalence of severe refractory asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Treatment of chronic rhinosinusitis with intranasal amphotericin B: A randomized, placebo-controlled, double-blind pilot trial Jens U. Ponikau, MD, David.

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma Stanley J. Szefler, MD, Kevin Murphy,

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Is 9 more than 2 also in allergic airway inflammation?

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma Kai-Michael Beeh, MD, Frank Kanniess, MD, Frank Wagner, MD, Cordula.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Badrul A. Chowdhury, MD, PhD

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Knemometry is more sensitive to systemic effects of inhaled corticosteroids in children with asthma than 24-hour urine cortisol excretion Bo Chawes,

Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers Robert A. Wise,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trials

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Reply Journal of Allergy and Clinical Immunology

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Effects of formoterol or salmeterol on impulse oscillometry in patients with persistent asthma Arvind Manoharan, MBChB, Alexander von Wilamowitz-Moellendorff,

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Blood eosinophils predict therapeutic effects of a GATA3-specific DNAzyme in asthma patients Norbert Krug, MD, Jens M. Hohlfeld, MD, Roland Buhl, MD,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

What is an “eosinophilic phenotype” of asthma?

Jeffrey M. Harris, MD, PhD, Christopher R

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Diagnosis and management of early asthma in preschool-aged children

Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids Michael Noonan, MD, Phillip Korenblat, MD, Sofia Mosesova, PhD,

Reply Journal of Allergy and Clinical Immunology

Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children Georgette Stern, MSc, Johan de Jongste, MD, Ralf.

Eckard Hamelmann, MD, Eric D

A randomized trial of methotrexate versus azathioprine for severe atopic eczema Mandy Elvira Schram, MD, Evelien Roekevisch, MD, Mariska Maria Geertruida.

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Severity assessment in asthma: An evolving concept

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Environmental factors and eosinophilic esophagitis

Advances in pediatric asthma in 2007

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies Frank C. Albers, MD, PhD, Robert G. Price,

Presentation transcript:

Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial Huib A.M. Kerstjens, MD, PhD, Bernd Disse, MD, PhD, Winfried Schröder-Babo, MD, Theo A. Bantje, MD, Martina Gahlemann, MD, Ralf Sigmund, Dipl-Math oec, Michael Engel, MD, Jan A. van Noord, MD Journal of Allergy and Clinical Immunology Volume 128, Issue 2, Pages 308-314 (August 2011) DOI: 10.1016/j.jaci.2011.04.039 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Screening, randomization, and study completion. Journal of Allergy and Clinical Immunology 2011 128, 308-314DOI: (10.1016/j.jaci.2011.04.039) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 FEV1 (A) and FVC (B) responses relative to baseline values within 3 hours after dosing after 8 weeks of treatment. The difference in level at 0:00 h is the trough effect of tiotropium administered 24 hours earlier. The measurement obtained at baseline (visit 2 before any maintenance or study medication) is defined as the baseline value. At the on-treatment visits, this was immediately followed by the usual medication (including ICS plus LABA), and this in turn was followed by the study medication. Error bars represent SEMs. Arrows indicate the timing of the maintenance medication: ICS plus LABA. Tiotropium R5, 5 μg of tiotropium; Tiotropium R10, 10 μg of tiotropium. Journal of Allergy and Clinical Immunology 2011 128, 308-314DOI: (10.1016/j.jaci.2011.04.039) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Twenty-four-hour FEV1 (A) and FVC (B) responses as shown in Fig 2 in the subgroup of patients with 24-hour assessments (n = 67). The baseline value was defined on visit 2 before any maintenance or study medication. At the on-treatment visits, this was immediately followed by the usual medication (including ICS plus LABA), which was followed in turn by the study medication. The afternoon dosing of ICS plus LABA treatment was also taken. Error bars represent SEMs. Arrows indicate the timing of the maintenance medication: ICS plus LABA. Tio R5, 5 μg of tiotropium; Tio R10, 10 μg of tiotropium. Journal of Allergy and Clinical Immunology 2011 128, 308-314DOI: (10.1016/j.jaci.2011.04.039) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Mean weekly morning PEF measured before dosing in the last 5 weeks of the 8–week treatment period. Note: the first 3 weeks of the treatment period were prespecified as probably reflecting a carryover effect of the previous treatment because there was no washout period between treatments. Error bars represent SEMs. Journal of Allergy and Clinical Immunology 2011 128, 308-314DOI: (10.1016/j.jaci.2011.04.039) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions